APLT News and Press, Applied Therapeutics Inc. From 08/12/22

Applied Therapeutics press release ( NASDAQ: APLT ): Q2 GAAP EPS of -$0.96 misses by $0.40 . Cash and cash equivalents and short-term investments totaled $67.7 million as of June 30, 2022, compared with $80.8 million at December 31, 2021. For further details see:...

Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multip...

Gold sponsor of the 2022 Galactosemia Foundation Conference; new website and educational resources as part of ongoing commitment to the Galactosemia community Applied Therapeutics to present research and clinical update NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Applied...

Gainers: Fujian Blue Hat Interactive Entertainment Technology (BHAT) +323%. F-star Therapeutics (FSTX) +59%. Rain Therapeutics (RAIN) +43%. The9 Limited (NCTY) +36%. Vroom (VRM) +33%. MSP Recovery (MSPR) +23%. uniQure (QURE) +22%. Azure Power Global (AZRE) +22%. Valneva (VALN) +21%. Anebulo P...

Gainers: F-star Therapeutics (FSTX) +57%. Valneva (VALN) +23%. Nutriband (NTRB) +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics (APLT) -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) ...

Applied Therapeutics ( APLT ) -22% on pricing $30M equity offering . Xenon Pharmaceuticals ( XENE ) -13% on pricing $250M equity offering . Clovis Oncology ( CLVS ) -10% Zai Lab ( ZLAB ) -9% on conversion of secondary listing in Ho...

Applied Therapeutics (NASDAQ:APLT) stock sank 24.3% after-hours on Wednesday after the firm has priced its underwritten public offering of 20.0M shares of its common stock, par value $0.0001/share, 10.0M pre-funded warrants to purchase common stock in lieu of common stock to ce...

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

Applied Therapeutics (NASDAQ:APLT) announced Wednesday its plans to issue shares and accompanying warrants in the underwritten public offering. The clinical stage biopharma company said it intends to use the net proceeds rom this offering for general corporate purposes. SVB Securities is acti...

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...